Kineta Return on Investment 2014-2024 | KANT
Current and historical return on investment (ROI) values for Kineta (KANT) over the last 10 years.
| Kineta ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-06-30 |
$-0.02B |
|
inf% |
| 2024-03-31 |
$-0.02B |
$-0.01B |
-750.00% |
| 2023-12-31 |
$-0.02B |
$0.00B |
-400.00% |
| 2023-09-30 |
$-0.04B |
$0.00B |
-894.12% |
| 2023-06-30 |
$-0.04B |
$0.01B |
-1085.71% |
| 2023-03-31 |
$-0.04B |
$0.00B |
-2800.00% |
| 2022-12-31 |
$-0.04B |
$0.01B |
-3280.00% |
| 2022-09-30 |
$0.00B |
|
-800.00% |
| 2022-06-30 |
$-0.00B |
|
-20.51% |
| 2022-03-31 |
$-0.01B |
|
-31.11% |
| 2021-12-31 |
$-0.01B |
$-0.00B |
-29.33% |
| 2021-09-30 |
$-0.07B |
$0.04B |
-117.65% |
| 2021-06-30 |
$-0.06B |
$0.05B |
-135.56% |
| 2021-03-31 |
$-0.06B |
$0.06B |
-179.84% |
| 2020-12-31 |
$-0.06B |
$0.07B |
-324.64% |
| 2020-09-30 |
$0.00B |
|
133.33% |
| 2020-06-30 |
$-0.00B |
|
-100.00% |
| 2020-03-31 |
$-0.02B |
|
-566.67% |
| 2019-12-31 |
$-0.03B |
$0.01B |
-833.33% |
| 2019-09-30 |
$-0.07B |
|
inf% |
| 2019-06-30 |
$-0.07B |
|
inf% |
| 2019-03-31 |
$-0.07B |
|
inf% |
| 2018-12-31 |
$-0.06B |
|
inf% |
| 2018-09-30 |
$-0.06B |
|
inf% |
| 2018-06-30 |
$-0.06B |
|
inf% |
| 2018-03-31 |
$-0.06B |
|
inf% |
| 2017-12-31 |
$-0.06B |
|
inf% |
| 2017-09-30 |
$-0.06B |
|
inf% |
| 2017-06-30 |
$-0.05B |
|
inf% |
| 2017-03-31 |
$-0.05B |
|
inf% |
| 2016-12-31 |
$-0.04B |
|
inf% |
| 2016-09-30 |
$-0.03B |
|
inf% |
| 2016-06-30 |
$-0.03B |
|
inf% |
| 2016-03-31 |
$-0.03B |
|
inf% |
| 2015-12-31 |
$-0.03B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
